STOCK TITAN

Cassava Sciences Inc - SAVA STOCK NEWS

Welcome to our dedicated news page for Cassava Sciences (Ticker: SAVA), a resource for investors and traders seeking the latest updates and insights on Cassava Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cassava Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cassava Sciences's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
-
Rhea-AI Summary
Cassava Sciences to present at Jefferies Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
conferences
Rhea-AI Summary
Cassava Sciences completes patient dosing in a 6-month trial of simufilam for Alzheimer's disease. Top-line results expected in Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.18%
Tags
none
-
Rhea-AI Summary
New data from European researchers show that simufilam can reverse altered filamin A protein (FLNA) in pituitary tumor cells, leading to improved cell signaling. The data suggest that improved cell signaling may enhance the clinical efficacy of an FDA-approved drug used to manage a type of pituitary tumor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.58%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.21%
Tags
Cassava Sciences Inc

Nasdaq:SAVA

SAVA Rankings

SAVA Stock Data

983.84M
40.20M
7.17%
32.7%
27.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Austin

About SAVA

refer to descriptions included in the company's filings with the securities and exchange commission for more information about the company. the company does not intend to update and does not take responsibility for any information published on linkedin.